29 July 2024
IXICO plc
("IXICO" or the "Company")
Further progress in HD consortium
Presentation of biomarker results and onboarding of new consortium partner
IXICO plc (AIM: IXI), the medical imaging advanced analytics company delivering insights in neuroscience reports further progress in the Huntington's disease imaging harmonization (HD-IH) consortium deploying IXICO's AI powered IXIQ.Ai analysis platform to develop and validate imaging biomarkers for HD. HD-IH was previously announced as a partnership between the CHDI Foundation, uniQure, PTC Therapeutics, and Asklepios BioPharmaceutical, and IXICO is pleased to announce the onboarding of an additional bio-pharma partner to HD-IH in June 2024. Over the past year, the expanding partnership has made significant progress in applying IXIQ.Ai to more than 6,000 MRI scans available to the consortium and generating the data required to demonstrate the utility of the obtained biomarker measurements as clinical trial endpoints.
IXICO's Dr Marina Papoutsi presented preliminary findings at the annual HD-TC conference in February 2024 in a poster entitled "Association between regional volume change and clinical change in Huntington's disease HD-ISS Stage 2 and Stage 3 participant". The presentation provides further evidence for the use of brain volume changes measured with IXIQ.Ai as an alternative trial endpoint to traditional clinical outcomes (surrogate endpoint). HD-IH continues to seek additional partners to expand its biomarker development program.
Dr Robin Wolz, Chief Scientific Officer of IXICO, commented:
"We are delighted with the progress made in the HD-IH consortium over the past year. The results presented at the HD-TC conference show how the initial data generated via this partnership provides additional evidence of the impact that MRI-based biomarkers have in HD clinical development. This further expansion in the number of HD-IH biopharmaceutical partners demonstrates the value this collaboration provides to the industry.
By completing the analysis of the available data over the remainder of 2024 and focusing on the resulting biomarker evidence, the consortium will provide unique scientific understanding and insights for successful operational implementation of those measurements in clinical development."
For further information please contact:
| IXICO plc | +44 (0) 20 3763 7499 | |||
| Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer |
| |||
|
| | |||
| Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker) | +44 (0) 20 7220 0500 | |||
| Giles Balleny / Dan Hodkinson (Corporate Finance) Michael F Johnson / Tamar Cranford Smith (Sales) |
| | ||
About IXICO
IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.
IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.
More information is available on www.IXICO.com and follow us on Twitter @IXICOnews
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.